 | • レポートコード：D0GIR-01306 • 出版社/出版日：GlobalInfoResearch / 2020年9月23日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、121ページ • 納品方法：Eメール • 産業分類：医療、製薬、バイオ |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、インフルエンザ（インフルエンザ）抗ウイルス薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。インフルエンザ（インフルエンザ）抗ウイルス薬の種類別市場規模（浸透阻害剤、脱皮阻害剤、DNAポリメラーゼ阻害剤、逆転写酵素阻害剤、タンパク質阻害剤、ノイラミニダーゼ阻害剤、広域抗ウイルス薬）、用途別市場規模（病院、クリニック、家庭、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Pfizer、Gilead Sciences、Johnson & Johnson、Roche、AbbVie、Sanofi、Amgen、Novartis、Merck & Co. (MSD)、GlaxoSmithKline (GSK)、Bayer、Takeda、AstraZeneca、Novo Nordisk、Teva、Bristol-Myers Squibb、Boehringer Ingelheim、Allergan、Eli Lilly ・地域別グローバル市場分析 2015年-2020年 ・インフルエンザ（インフルエンザ）抗ウイルス薬の北米市場（アメリカ、カナダ、メキシコ） ・インフルエンザ（インフルエンザ）抗ウイルス薬のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・インフルエンザ（インフルエンザ）抗ウイルス薬のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・インフルエンザ（インフルエンザ）抗ウイルス薬の南米市場（ブラジル、アルゼンチン） ・インフルエンザ（インフルエンザ）抗ウイルス薬の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：浸透阻害剤、脱皮阻害剤、DNAポリメラーゼ阻害剤、逆転写酵素阻害剤、タンパク質阻害剤、ノイラミニダーゼ阻害剤、広域抗ウイルス薬 ・用途別分析：病院、クリニック、家庭、その他 ・地域別市場規模予測 2021年-2025年 ・調査の結果・結論 |
Market Overview
The Influenza (Flu) Antiviral Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
The most likely (base case) scenario is that the global Influenza (Flu) Antiviral Drugs sales will be xx in 2020 from Influenza (Flu) Antiviral Drugs million in 2019, with a change xx% between 2019 and 2020. In addition, based on the latest study, it is to predict that the Covid-19 will be under control in key countries like the United States, Western Europe, East Asia, by the end of Q2 (June), and will resume normal production in Q3 and Q4, the global Influenza (Flu) Antiviral Drugs market size is expected to grow at xx% or more annually for the next five years.
This report also researches and evaluates the impact of Covid-19 outbreak on the Influenza (Flu) Antiviral Drugs industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Influenza (Flu) Antiviral Drugs and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.).
Market segmentation
Influenza (Flu) Antiviral Drugs market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Influenza (Flu) Antiviral Drugs market has been segmented into:
Penetration and Dehulling Inhibitors
DNA Polymerase Inhibitors
Reverse Transcriptase Inhibitors
Protein Inhibitors
Neuraminidase Inhibitors
Broad-spectrum Antiviral Drugs
By Application, Influenza (Flu) Antiviral Drugs has been segmented into:
Hospital
Clinic
Household
Others
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Influenza (Flu) Antiviral Drugs market presented in the report. This section sheds light on the sales growth of different regional and country-level Influenza (Flu) Antiviral Drugs markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Influenza (Flu) Antiviral Drugs market.
The report offers in-depth assessment of the growth and other aspects of the Influenza (Flu) Antiviral Drugs market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Competitive Landscape and Influenza (Flu) Antiviral Drugs Market Share Analysis
Influenza (Flu) Antiviral Drugs competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Influenza (Flu) Antiviral Drugs sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Influenza (Flu) Antiviral Drugs sales, revenue and market share for each player covered in this report.
The major players covered in Influenza (Flu) Antiviral Drugs are:
Pfizer
Gilead Sciences
Johnson & Johnson
Roche
AbbVie
Sanofi
Amgen
Novartis
Merck & Co. (MSD)
GlaxoSmithKline (GSK)
Bayer
Takeda
AstraZeneca
Novo Nordisk
Teva
Bristol-Myers Squibb
Boehringer Ingelheim
Allergan
Eli Lilly
Among other players domestic and global, Influenza (Flu) Antiviral Drugs market share data is available for global, North America, Europe, Asia-Pacific, Middle East & Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
1 Influenza (Flu) Antiviral Drugs Market Overview
1.1 Product Overview and Scope of Influenza (Flu) Antiviral Drugs
1.2 Classification of Influenza (Flu) Antiviral Drugs by Type
1.2.1 Global Influenza (Flu) Antiviral Drugs Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Type in 2019
1.2.3 Penetration and Dehulling Inhibitors
1.2.4 DNA Polymerase Inhibitors
1.2.5 Reverse Transcriptase Inhibitors
1.2.6 Protein Inhibitors
1.2.7 Neuraminidase Inhibitors
1.2.8 Broad-spectrum Antiviral Drugs
1.3 Global Influenza (Flu) Antiviral Drugs Market by Application
1.3.1 Overview: Global Influenza (Flu) Antiviral Drugs Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Household
1.3.5 Others
1.4 Global Influenza (Flu) Antiviral Drugs Market by Regions
1.4.1 Global Influenza (Flu) Antiviral Drugs Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Influenza (Flu) Antiviral Drugs (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Influenza (Flu) Antiviral Drugs Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Influenza (Flu) Antiviral Drugs Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Influenza (Flu) Antiviral Drugs Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Influenza (Flu) Antiviral Drugs Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Influenza (Flu) Antiviral Drugs Status and Prospect (2015-2025)
1.5 COVID-19 Outbreak: Influenza (Flu) Antiviral Drugs Industry Impact
1.5.1 COVID-19 Potential Implications for the Influenza (Flu) Antiviral Drugs
1.5.1.1 Scenario One: Very Optimistic: COVID-19 has No Influence on Influenza (Flu) Antiviral Drugs
1.5.1.2 Scenario Two: Optimistic: COVID-19 Will Be Under Control by the End of April
1.5.1.3 Scenario Three: Gloomy: COVID-19 Will Be Under Control Between Q3 and Q4
1.5.1.4 Scenario Four: Most Likely: COVID-19 Will Be Under Control by the End of Q2
1.5.2 Opportunity Analysis in Covid-19 Crisis
1.5.3 Market Risk and Restraints
1.5.4 Market Driving Force
2 Company Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Pfizer SWOT Analysis
2.1.4 Pfizer Product and Services
2.1.5 Pfizer Influenza (Flu) Antiviral Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.2 Gilead Sciences
2.2.1 Gilead Sciences Details
2.2.2 Gilead Sciences Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Gilead Sciences SWOT Analysis
2.2.4 Gilead Sciences Product and Services
2.2.5 Gilead Sciences Influenza (Flu) Antiviral Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.3 Johnson & Johnson
2.3.1 Johnson & Johnson Details
2.3.2 Johnson & Johnson Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Johnson & Johnson SWOT Analysis
2.3.4 Johnson & Johnson Product and Services
2.3.5 Johnson & Johnson Influenza (Flu) Antiviral Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.4 Roche
2.4.1 Roche Details
2.4.2 Roche Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Roche SWOT Analysis
2.4.4 Roche Product and Services
2.4.5 Roche Influenza (Flu) Antiviral Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.5 AbbVie
2.5.1 AbbVie Details
2.5.2 AbbVie Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 AbbVie SWOT Analysis
2.5.4 AbbVie Product and Services
2.5.5 AbbVie Influenza (Flu) Antiviral Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.6 Sanofi
2.6.1 Sanofi Details
2.6.2 Sanofi Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Sanofi SWOT Analysis
2.6.4 Sanofi Product and Services
2.6.5 Sanofi Influenza (Flu) Antiviral Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.7 Amgen
2.7.1 Amgen Details
2.7.2 Amgen Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Amgen SWOT Analysis
2.7.4 Amgen Product and Services
2.7.5 Amgen Influenza (Flu) Antiviral Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.8 Novartis
2.8.1 Novartis Details
2.8.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Novartis SWOT Analysis
2.8.4 Novartis Product and Services
2.8.5 Novartis Influenza (Flu) Antiviral Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.9 Merck & Co. (MSD)
2.9.1 Merck & Co. (MSD) Details
2.9.2 Merck & Co. (MSD) Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Merck & Co. (MSD) SWOT Analysis
2.9.4 Merck & Co. (MSD) Product and Services
2.9.5 Merck & Co. (MSD) Influenza (Flu) Antiviral Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.10 GlaxoSmithKline (GSK)
2.10.1 GlaxoSmithKline (GSK) Details
2.10.2 GlaxoSmithKline (GSK) Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 GlaxoSmithKline (GSK) SWOT Analysis
2.10.4 GlaxoSmithKline (GSK) Product and Services
2.10.5 GlaxoSmithKline (GSK) Influenza (Flu) Antiviral Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.11 Bayer
2.11.1 Bayer Details
2.11.2 Bayer Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Bayer SWOT Analysis
2.11.4 Bayer Product and Services
2.11.5 Bayer Influenza (Flu) Antiviral Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.12 Takeda
2.12.1 Takeda Details
2.12.2 Takeda Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 Takeda SWOT Analysis
2.12.4 Takeda Product and Services
2.12.5 Takeda Influenza (Flu) Antiviral Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.13 AstraZeneca
2.13.1 AstraZeneca Details
2.13.2 AstraZeneca Major Business and Total Revenue (Financial Highlights) Analysis
2.13.3 AstraZeneca SWOT Analysis
2.13.4 AstraZeneca Product and Services
2.13.5 AstraZeneca Influenza (Flu) Antiviral Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.14 Novo Nordisk
2.14.1 Novo Nordisk Details
2.14.2 Novo Nordisk Major Business and Total Revenue (Financial Highlights) Analysis
2.14.3 Novo Nordisk SWOT Analysis
2.14.4 Novo Nordisk Product and Services
2.14.5 Novo Nordisk Influenza (Flu) Antiviral Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.15 Teva
2.15.1 Teva Details
2.15.2 Teva Major Business and Total Revenue (Financial Highlights) Analysis
2.15.3 Teva SWOT Analysis
2.15.4 Teva Product and Services
2.15.5 Teva Influenza (Flu) Antiviral Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.16 Bristol-Myers Squibb
2.16.1 Bristol-Myers Squibb Details
2.16.2 Bristol-Myers Squibb Major Business and Total Revenue (Financial Highlights) Analysis
2.16.3 Bristol-Myers Squibb SWOT Analysis
2.16.4 Bristol-Myers Squibb Product and Services
2.16.5 Bristol-Myers Squibb Influenza (Flu) Antiviral Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.17 Boehringer Ingelheim
2.17.1 Boehringer Ingelheim Details
2.17.2 Boehringer Ingelheim Major Business and Total Revenue (Financial Highlights) Analysis
2.17.3 Boehringer Ingelheim SWOT Analysis
2.17.4 Boehringer Ingelheim Product and Services
2.17.5 Boehringer Ingelheim Influenza (Flu) Antiviral Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.18 Allergan
2.18.1 Allergan Details
2.18.2 Allergan Major Business and Total Revenue (Financial Highlights) Analysis
2.18.3 Allergan SWOT Analysis
2.18.4 Allergan Product and Services
2.18.3 Allergan Influenza (Flu) Antiviral Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.19 Eli Lilly
2.19.1 Eli Lilly Details
2.19.2 Eli Lilly Major Business and Total Revenue (Financial Highlights) Analysis
2.19.3 Eli Lilly SWOT Analysis
2.19.4 Eli Lilly Product and Services
2.19.5 Eli Lilly Influenza (Flu) Antiviral Drugs Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Influenza (Flu) Antiviral Drugs Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Influenza (Flu) Antiviral Drugs Players Market Share
3.2.2 Top 10 Influenza (Flu) Antiviral Drugs Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Influenza (Flu) Antiviral Drugs Revenue and Market Share by Regions
4.2 North America Influenza (Flu) Antiviral Drugs Revenue and Growth Rate (2015-2020)
4.3 Europe Influenza (Flu) Antiviral Drugs Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Influenza (Flu) Antiviral Drugs Revenue and Growth Rate (2015-2020)
4.5 South America Influenza (Flu) Antiviral Drugs Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Influenza (Flu) Antiviral Drugs Revenue and Growth Rate (2015-2020)
5 North America Influenza (Flu) Antiviral Drugs Revenue by Countries
5.1 North America Influenza (Flu) Antiviral Drugs Revenue by Countries (2015-2020)
5.2 USA Influenza (Flu) Antiviral Drugs Revenue and Growth Rate (2015-2020)
5.3 Canada Influenza (Flu) Antiviral Drugs Revenue and Growth Rate (2015-2020)
5.4 Mexico Influenza (Flu) Antiviral Drugs Revenue and Growth Rate (2015-2020)
6 Europe Influenza (Flu) Antiviral Drugs Revenue by Countries
6.1 Europe Influenza (Flu) Antiviral Drugs Revenue by Countries (2015-2020)
6.2 Germany Influenza (Flu) Antiviral Drugs Revenue and Growth Rate (2015-2020)
6.3 UK Influenza (Flu) Antiviral Drugs Revenue and Growth Rate (2015-2020)
6.4 France Influenza (Flu) Antiviral Drugs Revenue and Growth Rate (2015-2020)
6.5 Russia Influenza (Flu) Antiviral Drugs Revenue and Growth Rate (2015-2020)
6.6 Italy Influenza (Flu) Antiviral Drugs Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Influenza (Flu) Antiviral Drugs Revenue by Countries
7.1 Asia-Pacific Influenza (Flu) Antiviral Drugs Revenue by Countries (2015-2020)
7.2 China Influenza (Flu) Antiviral Drugs Revenue and Growth Rate (2015-2020)
7.3 Japan Influenza (Flu) Antiviral Drugs Revenue and Growth Rate (2015-2020)
7.4 Korea Influenza (Flu) Antiviral Drugs Revenue and Growth Rate (2015-2020)
7.5 India Influenza (Flu) Antiviral Drugs Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Influenza (Flu) Antiviral Drugs Revenue and Growth Rate (2015-2020)
8 South America Influenza (Flu) Antiviral Drugs Revenue by Countries
8.1 South America Influenza (Flu) Antiviral Drugs Revenue by Countries (2015-2020)
8.2 Brazil Influenza (Flu) Antiviral Drugs Revenue and Growth Rate (2015-2020)
8.3 Argentina Influenza (Flu) Antiviral Drugs Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Influenza (Flu) Antiviral Drugs by Countries
9.1 Middle East & Africa Influenza (Flu) Antiviral Drugs Revenue by Countries (2015-2020)
9.2 Saudi Arabia Influenza (Flu) Antiviral Drugs Revenue and Growth Rate (2015-2020)
9.3 UAE Influenza (Flu) Antiviral Drugs Revenue and Growth Rate (2015-2020)
9.4 Egypt Influenza (Flu) Antiviral Drugs Revenue and Growth Rate (2015-2020)
9.5 South Africa Influenza (Flu) Antiviral Drugs Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Influenza (Flu) Antiviral Drugs Revenue and Market Share by Type (2015-2020)
10.2 Global Influenza (Flu) Antiviral Drugs Market Forecast by Type (2019-2024)
10.3 Penetration and Dehulling Inhibitors Revenue Growth Rate (2015-2025)
10.4 DNA Polymerase Inhibitors Revenue Growth Rate (2015-2025)
10.5 Reverse Transcriptase Inhibitors Revenue Growth Rate (2015-2025)
10.6 Protein Inhibitors Revenue Growth Rate (2015-2025)
10.7 Neuraminidase Inhibitors Revenue Growth Rate (2015-2025)
10.8 Broad-spectrum Antiviral Drugs Revenue Growth Rate (2015-2025)
11 Global Influenza (Flu) Antiviral Drugs Market Segment by Application
11.1 Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Application (2015-2020)
11.2 Influenza (Flu) Antiviral Drugs Market Forecast by Application (2019-2024)
11.3 Hospital Revenue Growth (2015-2020)
11.4 Clinic Revenue Growth (2015-2020)
11.5 Household Revenue Growth (2015-2020)
11.6 Others Revenue Growth (2015-2020)
12 Global Influenza (Flu) Antiviral Drugs Market Size Forecast (2021-2025)
12.1 Global Influenza (Flu) Antiviral Drugs Market Size Forecast (2021-2025)
12.2 Global Influenza (Flu) Antiviral Drugs Market Forecast by Regions (2021-2025)
12.3 North America Influenza (Flu) Antiviral Drugs Revenue Market Forecast (2021-2025)
12.4 Europe Influenza (Flu) Antiviral Drugs Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Influenza (Flu) Antiviral Drugs Revenue Market Forecast (2021-2025)
12.6 South America Influenza (Flu) Antiviral Drugs Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Influenza (Flu) Antiviral Drugs Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US
Table 1. Global Influenza (Flu) Antiviral Drugs Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Influenza (Flu) Antiviral Drugs by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Influenza (Flu) Antiviral Drugs Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Influenza (Flu) Antiviral Drugs Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Global Influenza (Flu) Antiviral Drugs Market Size and Growth Estimation in Various Scenarios in 2020
Table 6. Pfizer Corporate Information, Location and Competitors
Table 7. Pfizer Influenza (Flu) Antiviral Drugs Major Business
Table 8. Pfizer Influenza (Flu) Antiviral Drugs Total Revenue (USD Million) (2017-2018)
Table 9. Pfizer SWOT Analysis
Table 10. Pfizer Influenza (Flu) Antiviral Drugs Product and Solutions
Table 11. Pfizer Influenza (Flu) Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 12. Gilead Sciences Corporate Information, Location and Competitors
Table 13. Gilead Sciences Influenza (Flu) Antiviral Drugs Major Business
Table 14. Gilead Sciences Influenza (Flu) Antiviral Drugs Total Revenue (USD Million) (2018-2019)
Table 15. Gilead Sciences SWOT Analysis
Table 16. Gilead Sciences Influenza (Flu) Antiviral Drugs Product and Solutions
Table 17. Gilead Sciences Influenza (Flu) Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 18. Johnson & Johnson Corporate Information, Location and Competitors
Table 19. Johnson & Johnson Influenza (Flu) Antiviral Drugs Major Business
Table 20. Johnson & Johnson Influenza (Flu) Antiviral Drugs Total Revenue (USD Million) (2017-2018)
Table 21. Johnson & Johnson SWOT Analysis
Table 22. Johnson & Johnson Influenza (Flu) Antiviral Drugs Product and Solutions
Table 23. Johnson & Johnson Influenza (Flu) Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 24. Roche Corporate Information, Location and Competitors
Table 25. Roche Influenza (Flu) Antiviral Drugs Major Business
Table 26. Roche Influenza (Flu) Antiviral Drugs Total Revenue (USD Million) (2017-2018)
Table 27. Roche SWOT Analysis
Table 28. Roche Influenza (Flu) Antiviral Drugs Product and Solutions
Table 29. Roche Influenza (Flu) Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 30. AbbVie Corporate Information, Location and Competitors
Table 31. AbbVie Influenza (Flu) Antiviral Drugs Major Business
Table 32. AbbVie Influenza (Flu) Antiviral Drugs Total Revenue (USD Million) (2017-2018)
Table 33. AbbVie SWOT Analysis
Table 34. AbbVie Influenza (Flu) Antiviral Drugs Product and Solutions
Table 35. AbbVie Influenza (Flu) Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 36. Sanofi Corporate Information, Location and Competitors
Table 37. Sanofi Influenza (Flu) Antiviral Drugs Major Business
Table 38. Sanofi Influenza (Flu) Antiviral Drugs Total Revenue (USD Million) (2017-2018)
Table 39. Sanofi SWOT Analysis
Table 40. Sanofi Influenza (Flu) Antiviral Drugs Product and Solutions
Table 41. Sanofi Influenza (Flu) Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 42. Amgen Corporate Information, Location and Competitors
Table 43. Amgen Influenza (Flu) Antiviral Drugs Major Business
Table 44. Amgen Influenza (Flu) Antiviral Drugs Total Revenue (USD Million) (2017-2018)
Table 45. Amgen SWOT Analysis
Table 46. Amgen Influenza (Flu) Antiviral Drugs Product and Solutions
Table 47. Amgen Influenza (Flu) Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 48. Novartis Corporate Information, Location and Competitors
Table 49. Novartis Influenza (Flu) Antiviral Drugs Major Business
Table 50. Novartis Influenza (Flu) Antiviral Drugs Total Revenue (USD Million) (2017-2018)
Table 51. Novartis SWOT Analysis
Table 52. Novartis Influenza (Flu) Antiviral Drugs Product and Solutions
Table 53. Novartis Influenza (Flu) Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 54. Merck & Co. (MSD) Corporate Information, Location and Competitors
Table 55. Merck & Co. (MSD) Influenza (Flu) Antiviral Drugs Major Business
Table 56. Merck & Co. (MSD) Influenza (Flu) Antiviral Drugs Total Revenue (USD Million) (2017-2018)
Table 57. Merck & Co. (MSD) SWOT Analysis
Table 58. Merck & Co. (MSD) Influenza (Flu) Antiviral Drugs Product and Solutions
Table 59. Merck & Co. (MSD) Influenza (Flu) Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 60. GlaxoSmithKline (GSK) Corporate Information, Location and Competitors
Table 61. GlaxoSmithKline (GSK) Influenza (Flu) Antiviral Drugs Major Business
Table 62. GlaxoSmithKline (GSK) Influenza (Flu) Antiviral Drugs Total Revenue (USD Million) (2017-2018)
Table 63. GlaxoSmithKline (GSK) SWOT Analysis
Table 64. GlaxoSmithKline (GSK) Influenza (Flu) Antiviral Drugs Product and Solutions
Table 65. GlaxoSmithKline (GSK) Influenza (Flu) Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 66. Bayer Corporate Information, Location and Competitors
Table 67. Bayer Influenza (Flu) Antiviral Drugs Major Business
Table 68. Bayer Influenza (Flu) Antiviral Drugs Total Revenue (USD Million) (2017-2018)
Table 69. Bayer SWOT Analysis
Table 70. Bayer Influenza (Flu) Antiviral Drugs Product and Solutions
Table 71. Bayer Influenza (Flu) Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 72. Takeda Corporate Information, Location and Competitors
Table 73. Takeda Influenza (Flu) Antiviral Drugs Major Business
Table 74. Takeda Influenza (Flu) Antiviral Drugs Total Revenue (USD Million) (2017-2018)
Table 75. Takeda SWOT Analysis
Table 76. Takeda Influenza (Flu) Antiviral Drugs Product and Solutions
Table 77. Takeda Influenza (Flu) Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 78. AstraZeneca Corporate Information, Location and Competitors
Table 79. AstraZeneca Influenza (Flu) Antiviral Drugs Major Business
Table 80. AstraZeneca Influenza (Flu) Antiviral Drugs Total Revenue (USD Million) (2017-2018)
Table 81. AstraZeneca SWOT Analysis
Table 82. AstraZeneca Influenza (Flu) Antiviral Drugs Product and Solutions
Table 83. AstraZeneca Influenza (Flu) Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 84. Novo Nordisk Corporate Information, Location and Competitors
Table 85. Novo Nordisk Influenza (Flu) Antiviral Drugs Major Business
Table 86. Novo Nordisk Influenza (Flu) Antiviral Drugs Total Revenue (USD Million) (2017-2018)
Table 87. Novo Nordisk SWOT Analysis
Table 88. Novo Nordisk Influenza (Flu) Antiviral Drugs Product and Solutions
Table 89. Novo Nordisk Influenza (Flu) Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 90. Teva Corporate Information, Location and Competitors
Table 91. Teva Influenza (Flu) Antiviral Drugs Major Business
Table 92. Teva Influenza (Flu) Antiviral Drugs Total Revenue (USD Million) (2017-2018)
Table 93. Teva SWOT Analysis
Table 94. Teva Influenza (Flu) Antiviral Drugs Product and Solutions
Table 95. Teva Influenza (Flu) Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 96. Bristol-Myers Squibb Corporate Information, Location and Competitors
Table 97. Bristol-Myers Squibb Influenza (Flu) Antiviral Drugs Major Business
Table 98. Bristol-Myers Squibb Influenza (Flu) Antiviral Drugs Total Revenue (USD Million) (2017-2018)
Table 99. Bristol-Myers Squibb SWOT Analysis
Table 100. Bristol-Myers Squibb Influenza (Flu) Antiviral Drugs Product and Solutions
Table 101. Bristol-Myers Squibb Influenza (Flu) Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 102. Boehringer Ingelheim Corporate Information, Location and Competitors
Table 103. Boehringer Ingelheim Influenza (Flu) Antiviral Drugs Major Business
Table 104. Boehringer Ingelheim Influenza (Flu) Antiviral Drugs Total Revenue (USD Million) (2017-2018)
Table 105. Boehringer Ingelheim SWOT Analysis
Table 106. Boehringer Ingelheim Influenza (Flu) Antiviral Drugs Product and Solutions
Table 107. Boehringer Ingelheim Influenza (Flu) Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 108. Allergan Influenza (Flu) Antiviral Drugs Type and Application
Table 109. Allergan Influenza (Flu) Antiviral Drugs Major Business
Table 110. Allergan Influenza (Flu) Antiviral Drugs Total Revenue (USD Million) (2017-2018)
Table 111. Allergan SWOT Analysis
Table 112. Allergan Influenza (Flu) Antiviral Drugs Product and Solutions
Table 113. Allergan Influenza (Flu) Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 114. Eli Lilly Corporate Information, Location and Competitors
Table 115. Eli Lilly Influenza (Flu) Antiviral Drugs Major Business
Table 116. Eli Lilly Influenza (Flu) Antiviral Drugs Total Revenue (USD Million) (2017-2018)
Table 117. Eli Lilly SWOT Analysis
Table 118. Eli Lilly Influenza (Flu) Antiviral Drugs Product and Solutions
Table 119. Eli Lilly Influenza (Flu) Antiviral Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 120. Global Influenza (Flu) Antiviral Drugs Revenue (Million USD) by Players (2015-2020)
Table 121. Global Influenza (Flu) Antiviral Drugs Revenue Share by Players (2015-2020)
Table 122. Global Influenza (Flu) Antiviral Drugs Revenue (Million USD) by Regions (2015-2020)
Table 123. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Regions (2015-2020)
Table 124. North America Influenza (Flu) Antiviral Drugs Revenue by Countries (2015-2020)
Table 125. North America Influenza (Flu) Antiviral Drugs Revenue Market Share by Countries (2015-2020)
Table 126. Europe Influenza (Flu) Antiviral Drugs Revenue (Million USD) by Countries (2015-2020)
Table 127. Asia-Pacific Influenza (Flu) Antiviral Drugs Revenue (Million USD) by Countries (2015-2020)
Table 128. South America Influenza (Flu) Antiviral Drugs Revenue by Countries (2015-2020)
Table 129. South America Influenza (Flu) Antiviral Drugs Revenue Market Share by Countries (2015-2020)
Table 130. Middle East and Africa Influenza (Flu) Antiviral Drugs Revenue (Million USD) by Countries (2015-2020)
Table 131. Middle East and Africa Influenza (Flu) Antiviral Drugs Revenue Market Share by Countries (2015-2020)
Table 132. Global Influenza (Flu) Antiviral Drugs Revenue (Million USD) by Type (2015-2020)
Table 133. Global Influenza (Flu) Antiviral Drugs Revenue Share by Type (2015-2020)
Table 134. Global Influenza (Flu) Antiviral Drugs Revenue Forecast by Type (2021-2025)
Table 135. Global Influenza (Flu) Antiviral Drugs Revenue by Application (2015-2020)
Table 136. Global Influenza (Flu) Antiviral Drugs Revenue Share by Application (2015-2020)
Table 137. Global Influenza (Flu) Antiviral Drugs Revenue Forecast by Application (2021-2025)
Table 138. Global Influenza (Flu) Antiviral Drugs Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Influenza (Flu) Antiviral Drugs Picture
Figure 2. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Type in 2019
Figure 3. Penetration and Dehulling Inhibitors Picture
Figure 4. DNA Polymerase Inhibitors Picture
Figure 5. Reverse Transcriptase Inhibitors Picture
Figure 6. Protein Inhibitors Picture
Figure 7. Neuraminidase Inhibitors Picture
Figure 8. Broad-spectrum Antiviral Drugs Picture
Figure 9. Influenza (Flu) Antiviral Drugs Revenue Market Share by Application in 2019
Figure 10. Hospital Picture
Figure 11. Clinic Picture
Figure 12. Household Picture
Figure 13. Others Picture
Figure 14. Global Influenza (Flu) Antiviral Drugs Revenue (USD Million) and Growth Rate (2015-2025)
Figure 15. North America Influenza (Flu) Antiviral Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Europe Influenza (Flu) Antiviral Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Asia-Pacific Influenza (Flu) Antiviral Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. South America Influenza (Flu) Antiviral Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 19. Middle East and Africa Influenza (Flu) Antiviral Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 20. Global Influenza (Flu) Antiviral Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 21. Global Influenza (Flu) Antiviral Drugs Revenue Share by Players in 2019
Figure 22. Global Top 5 Players Influenza (Flu) Antiviral Drugs Revenue Market Share in 2019
Figure 23. Global Top 10 Players Influenza (Flu) Antiviral Drugs Revenue Market Share in 2019
Figure 24. Key Players Market Share Trend
Figure 25. Global Influenza (Flu) Antiviral Drugs Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 26. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Regions (2015-2020)
Figure 27. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Regions in 2018
Figure 28. North America Influenza (Flu) Antiviral Drugs Revenue and Growth Rate (2015-2020)
Figure 29. Europe Influenza (Flu) Antiviral Drugs Revenue and Growth Rate (2015-2020)
Figure 30. Asia-Pacific Influenza (Flu) Antiviral Drugs Revenue and Growth Rate (2015-2020)
Figure 31. South America Influenza (Flu) Antiviral Drugs Revenue and Growth Rate (2015-2020)
Figure 32. Middle East and Africa Influenza (Flu) Antiviral Drugs Revenue and Growth Rate (2015-2020)
Figure 33. North America Influenza (Flu) Antiviral Drugs Revenue Market Share by Countries (2015-2020)
Figure 34. North America Influenza (Flu) Antiviral Drugs Revenue Market Share by Countries in 2019
Figure 35. USA Influenza (Flu) Antiviral Drugs Revenue and Growth Rate (2015-2020)
Figure 36. Canada Influenza (Flu) Antiviral Drugs Revenue and Growth Rate (2015-2020)
Figure 37. Mexico Influenza (Flu) Antiviral Drugs Revenue and Growth Rate (2015-2020)
Figure 38. Europe Influenza (Flu) Antiviral Drugs Revenue Market Share by Countries (2015-2020)
Figure 39. Europe Influenza (Flu) Antiviral Drugs Revenue Market Share by Countries in 2019
Figure 40. Germany Influenza (Flu) Antiviral Drugs Revenue and Growth Rate (2015-2020)
Figure 41. UK Influenza (Flu) Antiviral Drugs Revenue and Growth Rate (2015-2020)
Figure 42. France Influenza (Flu) Antiviral Drugs Revenue and Growth Rate (2015-2020)
Figure 43. Russia Influenza (Flu) Antiviral Drugs Revenue and Growth Rate (2015-2020)
Figure 44. Italy Influenza (Flu) Antiviral Drugs Revenue and Growth Rate (2015-2020)
Figure 45. Asia-Pacific Influenza (Flu) Antiviral Drugs Revenue Market Share by Countries (2015-2020)
Figure 46. Asia-Pacific Influenza (Flu) Antiviral Drugs Revenue Market Share by Countries in 2019
Figure 47. China Influenza (Flu) Antiviral Drugs Revenue and Growth Rate (2015-2020)
Figure 48. Japan Influenza (Flu) Antiviral Drugs Revenue and Growth Rate (2015-2020)
Figure 49. Korea Influenza (Flu) Antiviral Drugs Revenue and Growth Rate (2015-2020)
Figure 50. India Influenza (Flu) Antiviral Drugs Revenue and Growth Rate (2015-2020)
Figure 51. Southeast Asia Influenza (Flu) Antiviral Drugs Revenue and Growth Rate (2015-2020)
Figure 52. South America Influenza (Flu) Antiviral Drugs Revenue Market Share by Countries (2015-2020)
Figure 53. South America Influenza (Flu) Antiviral Drugs Revenue Market Share by Countries in 2019
Figure 54. Brazil Influenza (Flu) Antiviral Drugs Revenue and Growth Rate (2015-2020)
Figure 55. Argentina Influenza (Flu) Antiviral Drugs Revenue and Growth Rate (2015-2020)
Figure 56. Middle East and Africa Influenza (Flu) Antiviral Drugs Revenue Market Share by Countries (2015-2020)
Figure 57. Middle East and Africa Influenza (Flu) Antiviral Drugs Revenue Market Share by Countries in 2019
Figure 58. Saudi Arabia Influenza (Flu) Antiviral Drugs Revenue and Growth Rate (2015-2020)
Figure 59. UAE Influenza (Flu) Antiviral Drugs Revenue and Growth Rate (2015-2020)
Figure 60. Egypt Influenza (Flu) Antiviral Drugs Revenue and Growth Rate (2015-2020)
Figure 61. South Africa Influenza (Flu) Antiviral Drugs Revenue and Growth Rate (2015-2020)
Figure 62. Global Influenza (Flu) Antiviral Drugs Revenue Share by Type (2015-2020)
Figure 63. Global Influenza (Flu) Antiviral Drugs Revenue Share by Type in 2019
Figure 64. Global Influenza (Flu) Antiviral Drugs Market Share Forecast by Type (2021-2025)
Figure 65. Global Penetration and Dehulling Inhibitors Revenue Growth Rate (2015-2020)
Figure 66. Global DNA Polymerase Inhibitors Revenue Growth Rate (2015-2020)
Figure 67. Global Reverse Transcriptase Inhibitors Revenue Growth Rate (2015-2020)
Figure 68. Global Protein Inhibitors Revenue Growth Rate (2015-2020)
Figure 69. Global Neuraminidase Inhibitors Revenue Growth Rate (2015-2020)
Figure 70. Global Broad-spectrum Antiviral Drugs Revenue Growth Rate (2015-2020)
Figure 71. Global Influenza (Flu) Antiviral Drugs Revenue Share by Application (2015-2020)
Figure 72. Global Influenza (Flu) Antiviral Drugs Revenue Share by Application in 2019
Figure 73. Global Influenza (Flu) Antiviral Drugs Market Share Forecast by Application (2021-2025)
Figure 74. Global Hospital Revenue Growth Rate (2015-2020)
Figure 75. Global Clinic Revenue Growth Rate (2015-2020)
Figure 76. Global Household Revenue Growth Rate (2015-2020)
Figure 77. Global Others Revenue Growth Rate (2015-2020)
Figure 78. Global Influenza (Flu) Antiviral Drugs Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 79. Global Influenza (Flu) Antiviral Drugs Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 80. Global Influenza (Flu) Antiviral Drugs Revenue Market Share Forecast by Regions (2021-2025)
Figure 81. North America Influenza (Flu) Antiviral Drugs Revenue Market Forecast (2021-2025)
Figure 82. Europe Influenza (Flu) Antiviral Drugs Revenue Market Forecast (2021-2025)
Figure 83. Asia-Pacific Influenza (Flu) Antiviral Drugs Revenue Market Forecast (2021-2025)
Figure 84. South America Influenza (Flu) Antiviral Drugs Revenue Market Forecast (2021-2025)
Figure 85. Middle East and Africa Influenza (Flu) Antiviral Drugs Revenue Market Forecast (2021-2025)
Figure 86. Sales Channel: Direct Channel vs Indirect Channel
抗ウイルス薬の世界市場2020年：メーカー別、地域別、種類・用途別 Market Overview The global Antiviral Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 3.1% in the forecast period of 2020 to 2025 and will expected to reach USD 47600 million by 2025, from USD 42060 million in 2019. The Antiviral Drugs market…- COVID-19用特定抗ウイルス薬の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The Specific Antiviral Drugs for COVID-19 market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value cha…
- 抗ウイルス用漢方薬の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The Antiviral Traditional Chinese Medicine market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value ch…
- インフルエンザ（インフルエンザ）ワクチンの世界市場2020年：メーカー別、地域別、種類・用途別 Market Overview The Flu (Influenza) Vaccine market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimizatio…
- インフルエンザワクチンの世界市場2020年：メーカー別、地域別、種類・用途別 Market Overview The Vaccine for Influenza market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization,…